Adam J. Kole

Adam Kole practices at University of Alabama Birmingham Hospital in Birmingham, Alabama.

Adam Kole's NPI, 1679918940, was assigned on May 1, 2013. Adam Kole graduated from University of North Carolina at Chapel Hill School of Medicine in 2013. Adam Kole holds Alabama license MD.37192.

Adam Kole's primary practice is University of Alabama Birmingham Hospital, at 619 19th S St, Birmingham, AL 35211 in Jefferson County. The practice phone is (205) 731-9770.

Adam Kole's primary practice is University of Alabama Birmingham Hospital in Birmingham, Alabama. Adam Kole is also affiliated with UAB Hospital. The medical group on file is UAB Medicine. Dmand AI also links Adam Kole to 1 more hospital, 3 medical groups and 2 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Adam Kole practices, 4 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Adam Kole's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Adam Kole is licensed in Alabama.

CMS data shows 766 Medicare services from Adam Kole across 13 procedure codes in 2024, for 211 Medicare patients. Medicare paid $42,562 for them.

CMS counts 211 Medicare patients who saw Adam Kole in 2024. The largest group is 65 to 74, with 99 patients. 75% of them have high blood pressure, and 73% have cancer. 13% are also on Medicaid. Their average risk score is 2.07, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Adam Kole's median patient age at 71, with 40% women.

In 2024, Adam Kole wrote 75 Medicare Part D claims for 35 patients. 92% of them were for generic drugs. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $190 in total drug cost. In 2023, CMS named 27 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Adam Kole for performance year 2024, reported as part of a group. Adam Kole accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Adam Kole as offering telehealth.

Dmand AI links 16 papers to Adam Kole, published from 2016 to 2025. 2024 was the busiest year, with 3. The most frequent topics are Lung Neoplasms, Tomography, X-Ray Computed and Biomarkers, Tumor. Adam Kole has published most often in Adv Radiat Oncol. Adam Kole's most frequent co-authors are Craig Steven Schneider, MD, Michael Soike and Drexell H. Boggs, MD.

Dmand AI links Adam Kole to 2 clinical trials. 2 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung and Carcinoma, Bronchogenic.

CMS Open Payments shows 21 general payments to Adam Kole from 10 drug and device companies from 2021 to 2025. Speaker and faculty fees make up the largest share, 95% of the total. Medtronic, Inc. paid the most, $10,132.

Adam Kole graduated from University of North Carolina at Chapel Hill School of Medicine in 2013.